

U.S. Nuclear Regulatory Commission Public Meeting Summary

Title: Public Meeting to Discuss the Draft Environmental Impact Statement Supplement Related to the Operating License for the SHINE Medical Isotope Production Facility

Meeting Identifier: 20220659

Date of Meetings: Wednesday, July 27, 2022

Location: Webinar

Type of Meeting: Comment-Gathering Meeting

Purpose of the Meeting(s):

To gather comments on the draft supplement to the environmental statement on the construction permit related to the operating license application for the SHINE Medical Isotope Production Facility (SHINE facility)

General Details:

The U.S. Nuclear Regulatory Commission (NRC) held a public commenting meeting as part of the commenting process for the draft supplement to the environmental statement on the construction permit related to the operating license application for the SHINE facility. The meeting started at 6:00 p.m. CT and ended at 8:00 p.m. CT, although primary discussions were finished by 6:30 p.m. CT. The meeting began with a brief review of meeting ground rules, followed by a presentation by the NRC staff on the NRC's regulatory role, a brief background on the SHINE facility, details involving the environmental review, the staff's preliminary findings, and environmental review milestones, as well as how the public can submit comments. The presentations emphasized that comments provided on or before August 22, 2022, would be considered in the staff's work towards the final supplement. Any comments received after that date would be considered if possible. There was an opportunity for attendees to ask questions about the NRC staff's presentation followed by an opportunity for members of the public to provide oral comments on the draft Supplemental Environmental Impact Statement. One participant asked a question about the safety review.

Approximately 10 non-NRC staff attended the meeting. The participants included members of the public, as well as representatives of SHINE Technologies, LLC (SHINE), Massachusetts Institute of Technology, and KL Gates, LLP.

Summary of Presentation:

The staff discussed that in 2015, the NRC and the U.S. Department of Energy, National Nuclear Security Administration (DOE-NNSA) issued NUREG-2183, "Environmental Impact Statement for the Construction Permit for the SHINE Medical Radioisotope Production Facility," which discussed the environmental impacts of constructing, operating, and decommissioning the SHINE facility in Janesville, Wisconsin. In 2016, at the conclusion of its safety and environmental reviews, the NRC issued a construction permit for the SHINE facility. In July 2019, SHINE submitted to the NRC an application for an operating license for the SHINE facility.

When a final environmental impact statement (FEIS) has been prepared in connection with the issuance of a construction permit for a facility, the NRC is required to prepare a supplement to the FEIS in connection with any issuance of an operating license for that facility in accordance with title 10 of the *Code of Federal Regulations* (10 CFR) part 51.95(b). This supplement updates the prior environmental review and only covers matters that differ from those or that reflect significant new information relative to that discussed in the FEIS. Accordingly, in response to SHINE's operating license application, the NRC and the DOE-NNSA staff have considered whether there is any new information with respect to the environment or the environmental impacts of the SHINE facility, including information that is different from that considered in NUREG-2183. The NRC staff did not identify any information that presents a seriously different picture of the environmental consequences of constructing, operating, and decommissioning the SHINE facility.

After weighing the environmental, economic, technical, and other benefits against environmental and other costs, the NRC staff's preliminary recommendation, unless safety issues mandate otherwise, is that the operating license be issued as proposed. The NRC staff based its recommendation on the following:

- the application, including SHINE's supplemental environmental report;
- consultation with Federal, State, Tribal, and local agencies;
- the staff's independent review; and
- the consideration of public comments.

The staff ended the meeting by stressing that the closing date for submitting comments on the draft supplement is August 22, 2022. In addition to providing comments at the meeting, comments can be: (1) mailed to the Office of Administration Mailstop TWFN7A60M, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001; (2) submitted online using the Federal Rulemaking website at [regulations.gov](https://www.regulations.gov) (Docket ID: NRC-2022-0135); or (3) submitted electronically by email to SHINEEnvironmental@nrc.gov.

Action Items/Next Steps:

The NRC staff will address any comments received during the commenting period as part of the licensing of the SHINE facility. The NRC staff will develop and publish a final Supplement to the Environmental Impact Statement to NUREG-2138, "NRC's Regulatory Role SHINE Background Environmental Review Preliminary Findings Environmental Review Milestones Submitting Public Comments." The NRC staff's responses to the comments received on the draft supplement will be included in appendix A of the final supplement. Concurrently, the NRC staff will also be preparing a safety evaluation report which documents the staff's independent safety evaluation.

Attachments:

- List of Attendees
- Meeting description and agenda – ML22187A040
- NRC staff presentation – ML22206A042
- Meeting transcript – ML22258A314

List of Attendees

July 27, 2022, Public Meeting to Discuss the Draft Environmental Impact Statement Supplement Related to the Operating License for the SHINE Medical Isotope Production Facility

NAME	AFFILIATION
Michael Balazik	Nuclear Regulatory Commission (NRC)
Allan Barker	NRC
Scott Burnell	NRC
Jennifer Davis	NRC
Yawar Faraz	NRC
Robert Hoffman	NRC
Caroline Hsu	NRC
Nancy Martinez	NRC
John Moses	NRC
Sayvon Norman	NRC
Lance Rakovan	NRC
Carolyn Wolf	NRC
Jeffrey Bartelme	SHINE Technologies, LLC
Roy Brown	Curium Pharma
Milton Concepcion	Constellation Nuclear
Jim Costedio	SHINE Technologies, LLC
Lin-wen Hu	Massachusetts Institute of Technology
Jair Mengatti	Instituto de Pesquisas Energéticas e Nucleares
Patrick O'Connell	SHINE Technologies, LLC
Mike L. O'Neill	KL Gates, LLP